- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05678322
Optimizing Timing of rhPSMA-7.3 (18F) for Assessing Site(s) of Recurrent Disease Following Radical Prostatectomy
January 9, 2024 updated by: NYU Langone Health
All men following Radical Prostatectomy (RP) at NYU Langone Health undergo routine prostate specific antigen (PSA) testing in order to identify disease recurrence.
By consensus, a BCR following RP occurs once the PSA > 0.2 ng/ml/ Biochemical recurrence often develops years prior to clinical evidence of disease recurrence.
Early identification of the site(s) of disease recurrence enables early salvage intervention.
Men will be eligible for the study at the point in time their post-prostatectomy PSA level first becomes >0.2 ng/ml.
Only those patients with rhPSMA-7.3
(18F) identifiable disease (local, nodal or systemic) will be offered salvage intervention per standard of care.
All patients with a negative initial rhPSMA-7.3
(18F) scan will undergo a second scan when the PSA is > 0,5 ng/ml or one year after the initial PET study.
The salvage interventions will be at the discretion of the investigator.
The study will compare the diagnostic yield of the first and second rhPSMA-7.3
(18F) studies.
Study Overview
Status
Recruiting
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Estimated)
22
Phase
- Phase 3
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Herbert Lepor, MD
- Phone Number: 646-825-6340
- Email: Herbert.lepor@nyulangone.org
Study Contact Backup
- Name: Rozalba Gogaj, MD, MPH
- Phone Number: 646-825-6356
- Email: Rozalba.gogaj@nyulangone.org
Study Locations
-
-
New York
-
New York, New York, United States, 10016
- Recruiting
- Smilow Comprehensive Prostate Cancer Center
-
Contact:
- Herbert Lepor, MD
- Phone Number: 646-825-6340
- Email: Herbert.lepor@nyulangone.org
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 100 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
Eligible patients will include all men between age 18 -100 years old,-that have had RP, at the first point in time the PSA > 0.2 ng/ml.
Exclusion Criteria:
- Any contraindication for MRI imaging.
- Prior allergic reaction to rhPSMA-7.3 (18F).
- Patient refuses rhPSMA-7.3 (18F) PET/MRI.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Diagnostic
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Patients with PSA > 0.2 ng/ml following Radical Prostatectomy
Men will be eligible for the study when their post-prostatectomy PSA level is initially observed to be PSA >0.2ng/ml.
All participants will receive a baseline rhPSMA-7.3
(18F) MRI scan within a month of enrollment, and the second rhPSMA-7.3
(18F) scan will be performed within a year of the initial scan.
Only those participants with rhPSMA-7.3
(18F) identifiable disease during the initial scan will be offered salvage intervention per standard of care.
All participants with a negative initial rhPSMA-7.3
(18F) scan will undergo a second scan when the PSA> 0.5 ng/ml or one year after the initial PET scan.
The salvage intervention will be at the discretion of the investigator.
|
Under development for the diagnosis of prostate cancer by Blue Earth Diagnostics.
rhPSMA-7.3
(18F) will be administered intravenously as a single-dose injection.
The molecular structure of the drug substance comprises a prostate-specific membrane antigen (PSMA) binding motif, a peptide spacer, an 18F-radiolabeled silicon fluoride acceptor moiety and a gallium chelator complex.
Other Names:
rhPSMA-7.3
(18F) PET MRI imaging will be conducted once at baseline and a second time within one year of the initial scan.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change from Baseline in Percentage of Positive PCa Screens
Time Frame: Baseline, Up to Month 24
|
This measurement will calculate the change in the percentage of participants who screen positive for prostate cancer (PCa) at the baseline rhPSMA-7.3
(18F) scan vs. the second scan.
|
Baseline, Up to Month 24
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Investigators
- Principal Investigator: Herbert Lepor, MD, NYU Langone Medical Center
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
January 31, 2023
Primary Completion (Estimated)
March 1, 2024
Study Completion (Estimated)
June 1, 2025
Study Registration Dates
First Submitted
December 28, 2022
First Submitted That Met QC Criteria
December 28, 2022
First Posted (Actual)
January 10, 2023
Study Record Updates
Last Update Posted (Actual)
January 10, 2024
Last Update Submitted That Met QC Criteria
January 9, 2024
Last Verified
January 1, 2024
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 22-00547
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Yes
Studies a U.S. FDA-regulated device product
Yes
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Prostate Cancer
-
Roswell Park Cancer InstituteRecruitingObesity | Overweight | Cancer Survivor | Prostate Adenocarcinoma | Stage I Prostate Cancer | Stage II Prostate Cancer | Stage III Prostate Cancer | Stage IV Prostate Cancer | Stage IIA Prostate Cancer | Stage IIB Prostate Cancer | Stage IVA Prostate Cancer | Stage IVB Prostate Cancer | Stage A Prostate Cancer | Stage... and other conditionsUnited States
-
Sidney Kimmel Cancer Center at Thomas Jefferson...Regeneron Pharmaceuticals; Prostate Cancer FoundationWithdrawnStage III Prostate Cancer | Stage IV Prostate Cancer | Stage IVA Prostate Cancer | Stage IVB Prostate Cancer | Stage IIIA Prostate Cancer | Stage IIIB Prostate Cancer | Stage IIIC Prostate Cancer
-
University of Southern CaliforniaNational Cancer Institute (NCI); SanofiTerminatedDiarrhea | Recurrent Prostate Cancer | Hormone-resistant Prostate Cancer | Stage I Prostate Cancer | Stage III Prostate Cancer | Stage IV Prostate Cancer | Stage IIA Prostate Cancer | Stage IIB Prostate CancerUnited States
-
Jonsson Comprehensive Cancer CenterNational Cancer Institute (NCI)CompletedRecurrent Prostate Cancer | Stage I Prostate Cancer | Stage III Prostate Cancer | Adenocarcinoma of the Prostate | Stage IV Prostate Cancer | Stage IIA Prostate Cancer | Stage IIB Prostate CancerUnited States
-
Ryan Kohlbrenner, MDRadiological Society of North AmericaCompletedProstate Adenocarcinoma | Stage IV Prostate Cancer AJCC v8 | Prostate Carcinoma | Stage IIIA Prostate Cancer AJCC v8 | Stage IIIB Prostate Cancer AJCC v8 | Stage IIC Prostate Cancer AJCC v8 | Stage III Prostate Cancer AJCC v8 | Stage IIIC Prostate Cancer AJCC v8 | Stage IVA Prostate Cancer AJCC v8 | Stage...United States
-
Jonsson Comprehensive Cancer CenterProgenics Pharmaceuticals, Inc.TerminatedRandomized Trial of PSMA PET Scan Before Definitive Radiation Therapy for Prostate Cancer (PSMA-dRT)Stage II Prostate Cancer AJCC v8 | Stage IIIA Prostate Cancer AJCC v8 | Stage IIIB Prostate Cancer AJCC v8 | Stage IIC Prostate Cancer AJCC v8 | Stage III Prostate Cancer AJCC v8 | Stage IIIC Prostate Cancer AJCC v8 | Stage IIA Prostate Cancer AJCC v8 | Stage IIB Prostate Cancer AJCC v8 | Stage I Prostate...United States
-
Ohio State University Comprehensive Cancer CenterRiverside Methodist HospitalCompletedStage I Prostate Cancer | Stage III Prostate Cancer | Stage IV Prostate Cancer | Stage IIA Prostate Cancer | Stage IIB Prostate CancerUnited States
-
University of California, IrvineCompletedRecurrent Prostate Cancer | Stage I Prostate Cancer | Stage III Prostate Cancer | Adenocarcinoma of the Prostate | Stage IIA Prostate Cancer | Stage IIB Prostate CancerUnited States
-
NRG OncologyNational Cancer Institute (NCI)RecruitingProstate Adenocarcinoma | Stage I Prostate Cancer AJCC v8 | Stage II Prostate Cancer AJCC v8 | Stage IIIA Prostate Cancer AJCC v8 | Stage IIIB Prostate Cancer AJCC v8 | Stage IIC Prostate Cancer AJCC v8 | Stage III Prostate Cancer AJCC v8 | Stage IIIC Prostate Cancer AJCC v8 | Stage IVA Prostate Cancer... and other conditionsUnited States
-
Mayo ClinicNational Cancer Institute (NCI)WithdrawnStage I Prostate Cancer AJCC v8 | Stage II Prostate Cancer AJCC v8 | Stage IIIA Prostate Cancer AJCC v8 | Stage IIIB Prostate Cancer AJCC v8 | Stage IIC Prostate Cancer AJCC v8 | Stage III Prostate Cancer AJCC v8 | Stage IIIC Prostate Cancer AJCC v8 | Stage IIA Prostate Cancer AJCC v8 | Stage IIB Prostate...United States
Clinical Trials on 18F-Labeled Positron Emission Tomography (PET) Diagnostic Agent
-
Amsterdam UMC, location VUmcZonMw: The Netherlands Organisation for Health Research and DevelopmentEnrolling by invitation
-
National Cancer Institute (NCI)Completed
-
National Cancer Institute (NCI)TerminatedKidney Neoplasms | Carcinoma, Renal CellUnited States
-
University of UtahCompletedMetastatic Prostate Carcinoma | Stage IV Prostate Cancer | Prostate Carcinoma Metastatic in the BoneUnited States
-
Neil M Rofsky, MD, MHACompletedAlzheimer Disease | Cognitive DeclineUnited States
-
University Hospital, BordeauxRecruiting
-
Stanford UniversityNational Cancer Institute (NCI)CompletedPancreatic Carcinoma | Healthy SubjectUnited States
-
Thomas HopeCompletedHyperparathyroidism, PrimaryUnited States
-
M.D. Anderson Cancer CenterGE HealthcareWithdrawn
-
Vanderbilt-Ingram Cancer CenterNational Institutes of Health (NIH)RecruitingHead and Neck Squamous Cell Carcinoma | Brain MetastasesUnited States